Orphan Drug Status Granted for Marshall Edwards' Investigational Anti-Cancer Drug Triphendiol (NV-196) NEW CANAAN, CT--(Marketwire - January 22, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL) announced today that its triphendiol (previously known as NV-196) has been granted orphan drug status by the...

Novogen NV-128 Induces Novel Mode of Cell Death in Cancer Cells SAN FRANCISCO, CA--(Marketwire - October 24, 2007) - Laboratory studies presented late yesterday at the annual AACR/EORTC/NCI Molecular Targets and Cancer Therapeutics conference demonstrate that...